Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Healing II: Complications01:24

Healing II: Complications

Complications during healing arise when tissue repair is altered by local or systemic factors. These changes involve abnormal collagen deposition, altered biomechanics, and reduced vascular supply, impairing restoration of normal structure and function.Loss of FunctionScar tissue differs significantly from the original tissue it replaces. In the skin, fibrosis lacks adnexal structures such as hair follicles, sebaceous glands, and sweat glands. Their absence reduces tactile sensitivity, impairs...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST.

Rheumatology (Oxford, England)·2026
Same author

Increased Mortality in Patients with Bullous Pemphigoid: A Nationwide Population-based Cohort Study of 5,738 Patients in Sweden.

Acta dermato-venereologica·2026
Same author

Associations between bullous pemphigoid and comorbidities: A Swedish nationwide cohort study of 5,738 patients.

Journal of multimorbidity and comorbidity·2026
Same author

Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

mAbs·2026
Same author

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Psoriasis (Auckland, N.Z.)·2026
Same author

Integrated Host Genetics and Skin Microbiome Profiling Suggest an HLA-C-Peptostreptococcus Axis in Psoriasis.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jun 24, 2026

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
07:40

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay

Published on: April 28, 2022

Keloid scarring: bench and bedside.

Oliver Seifert1, Ulrich Mrowietz

  • 1Department of Dermatology, County Hospital Ryhov, Jonkoping 55185, Sweden. oliver.seifert@lj.se

Archives of Dermatological Research
|April 11, 2009
PubMed
Summary
This summary is machine-generated.

Keloid scarring results from altered wound healing, impacting patient quality of life. Current research explores genetic and molecular factors to develop novel keloid treatments.

More Related Videos

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
07:40

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay

Published on: April 28, 2022

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Area of Science:

  • Dermatology
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Wound healing is essential for survival, but adult scarring differs from fetal healing.
  • Aberrant wound healing processes lead to pathological scarring, including hypertrophic scars and keloids.
  • Patient quality of life is significantly impaired by keloid and hypertrophic scarring.

Purpose of the Study:

  • To review the genetic and molecular basis of keloid formation.
  • To summarize current research trends in keloid scarring.
  • To highlight emerging therapeutic strategies for keloid treatment.

Main Methods:

  • Literature review of genetic, molecular, and clinical studies on keloid scarring.
  • Analysis of recent advancements in keloid treatment modalities.
  • Synthesis of current understanding of scar spectrum and clinical aspects.

Main Results:

  • Significant progress has been made in identifying factors contributing to keloid development.
  • Novel therapeutic targets and treatments, including imiquimod and growth factor inhibitors, are emerging.
  • Despite advances, a unifying theory for keloid pathogenesis remains elusive.

Conclusions:

  • Understanding the genetic and molecular underpinnings of keloids is crucial for therapeutic development.
  • Ongoing research focuses on novel treatments to improve outcomes for keloid patients.
  • Further investigation is needed to elucidate a comprehensive theory of keloid formation.